Department of Emergency Medicine, Pamukkale University, Denizli, Turkey.
Emerg Med J. 2012 Nov;29(11):902-5. doi: 10.1136/emermed-2011-200165. Epub 2011 Dec 20.
To determine the analgesic efficacy and safety of intravenous single-dose paracetamol versus morphine in patients presenting to the emergency department with renal colic.
A randomised double-blind study was performed to compare the efficacy of intravenous paracetamol (1 g) and 0.1 mg/kg morphine in patients with renal colic. The efficacy of the study drugs was measured by a visual analogue scale and a verbal rating scale at baseline and after 15 and 30 min. The adverse effects and need for rescue medication (1 μg/kg intravenous fentanyl) were also recorded at the end of the study.
133 patients were eligible for enrolment in the study, with 73 patients included in the final analysis (38 in the paracetamol group and 35 in the morphine group). The mean±SD age of the subjects was 30.2±8.6 years and 51 (70%) were men. The mean reduction in scores at 30 min after study drug administration was 63.7 mm (95% CI 57 to 71) for paracetamol and 56.6 mm (95% CI 48 to 65) for morphine. The difference between pain reduction scores for the two groups at 30 min was 7.1 mm (95% CI -18 to 4), demonstrating no statistical or clinical significance. Two adverse events (5.3%) were recorded in the paracetamol group and five (14.3%) in the morphine group (difference 9%, 95% CI -7% to 26%).
Intravenous paracetamol is effective in treating patients presenting with renal colic to the emergency department. CLINICAL TRIALS REGISTRATION NO: ClinicalTrials.gov ID number NCT01318187.
比较静脉单次剂量扑热息痛与吗啡在急诊肾绞痛患者中的镇痛效果和安全性。
本研究采用随机、双盲的方法比较了静脉注射扑热息痛(1 克)和 0.1 毫克/公斤吗啡在肾绞痛患者中的疗效。在基线时和 15 分钟和 30 分钟后,使用视觉模拟量表和口头评分量表来评估研究药物的疗效。在研究结束时还记录了不良反应和需要抢救药物(1μg/kg 静脉注射芬太尼)的情况。
133 例患者符合纳入研究标准,最终有 73 例患者进入最终分析(扑热息痛组 38 例,吗啡组 35 例)。受试者的平均年龄为 30.2±8.6 岁,其中 51 例(70%)为男性。用药后 30 分钟,扑热息痛组疼痛评分平均下降 63.7 毫米(95%可信区间 57 至 71),吗啡组下降 56.6 毫米(95%可信区间 48 至 65)。两组在 30 分钟时疼痛缓解评分的差异为 7.1 毫米(95%可信区间 -18 至 4),无统计学或临床意义。扑热息痛组有 2 例(5.3%)不良反应,吗啡组有 5 例(14.3%)(差异 9%,95%可信区间 -7%至 26%)。
静脉注射扑热息痛对急诊肾绞痛患者有效。
ClinicalTrials.gov 注册号 NCT01318187。